2yj2: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==CATHEPSIN L WITH A NITRILE INHIBITOR== | ==CATHEPSIN L WITH A NITRILE INHIBITOR== | ||
<StructureSection load='2yj2' size='340' side='right' caption='[[2yj2]], [[Resolution|resolution]] 1.15Å' scene=''> | <StructureSection load='2yj2' size='340' side='right'caption='[[2yj2]], [[Resolution|resolution]] 1.15Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2yj2]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2YJ2 OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[2yj2]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2YJ2 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=2YJ2 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=YJ2:(2S,4R)-1-[1-(4-BROMOPHENYL)CYCLOPROPYL]CARBONYL-4-(2-CHLOROPHENYL)SULFONYL-N-[1-(IMINOMETHYL)CYCLOPROPYL]PYRROLIDINE-2-CARBOXAMIDE'>YJ2</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=YJ2:(2S,4R)-1-[1-(4-BROMOPHENYL)CYCLOPROPYL]CARBONYL-4-(2-CHLOROPHENYL)SULFONYL-N-[1-(IMINOMETHYL)CYCLOPROPYL]PYRROLIDINE-2-CARBOXAMIDE'>YJ2</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1cjl|1cjl]], [[1cs8|1cs8]], [[2xu4|2xu4]], [[2vhs|2vhs]], [[1icf|1icf]], [[2xu3|2xu3]], [[1mhw|1mhw]], [[2xu5|2xu5]], [[2xu1|2xu1]], [[2yj8|2yj8]], [[2yj9|2yj9]], [[2yjb|2yjb]], [[2yjc|2yjc]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1cjl|1cjl]], [[1cs8|1cs8]], [[2xu4|2xu4]], [[2vhs|2vhs]], [[1icf|1icf]], [[2xu3|2xu3]], [[1mhw|1mhw]], [[2xu5|2xu5]], [[2xu1|2xu1]], [[2yj8|2yj8]], [[2yj9|2yj9]], [[2yjb|2yjb]], [[2yjc|2yjc]]</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cathepsin_L Cathepsin L], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.15 3.4.22.15] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Cathepsin_L Cathepsin L], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.22.15 3.4.22.15] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=2yj2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2yj2 OCA], [http://pdbe.org/2yj2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2yj2 RCSB], [http://www.ebi.ac.uk/pdbsum/2yj2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2yj2 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
Line 22: | Line 22: | ||
==See Also== | ==See Also== | ||
*[[Cathepsin|Cathepsin]] | *[[Cathepsin 3D structures|Cathepsin 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
Line 29: | Line 29: | ||
[[Category: Cathepsin L]] | [[Category: Cathepsin L]] | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Large Structures]] | |||
[[Category: Banner, D W]] | [[Category: Banner, D W]] | ||
[[Category: Benz, J M]] | [[Category: Benz, J M]] |
Revision as of 15:53, 22 July 2020
CATHEPSIN L WITH A NITRILE INHIBITORCATHEPSIN L WITH A NITRILE INHIBITOR
Structural highlights
Function[CATL1_HUMAN] Important for the overall degradation of proteins in lysosomes. Publication Abstract from PubMedIn two series of small-molecule ligands, one inhibiting human cathepsin L (hcatL) and the other MEK1 kinase, biological affinities were found to strongly increase when an aryl ring of the inhibitors is substituted with the larger halogens Cl, Br, and I, but to decrease upon F substitution. X-ray co-crystal structure analyses revealed that the higher halides engage in halogen bonding (XB) with a backbone CO in the S3 pocket of hcatL and in a back pocket of MEK1. While the S3 pocket is located at the surface of the enzyme, which provides a polar environment, the back pocket in MEK1 is deeply buried in the protein and is of pronounced apolar character. This study analyzes environmental effects on XB in protein-ligand complexes. It is hypothesized that energetic gains by XB are predominantly not due to water replacements but originate from direct interactions between the XB donor (C(aryl) X) and the XB acceptor (CO) in the correct geometry. New X-ray co-crystal structures in the same crystal form (space group P2(1) 2(1) 2(1) ) were obtained for aryl chloride, bromide, and iodide ligands bound to hcatL. These high-resolution structures reveal that the backbone CO group of Gly61 in most hcatL co-crystal structures maintains water solvation while engaging in XB. An arylCF(3) -substituted ligand of hcatL with an unexpectedly high affinity was found to adopt the same binding geometry as the aryl halides, with the CF(3) group pointing to the CO group of Gly61 in the S3 pocket. In this case, a repulsive F(2) CFOC contact apparently is energetically overcompensated by other favorable protein-ligand contacts established by the CF(3) group. Halogen Bonding at the Active Sites of Human Cathepsin L and MEK1 Kinase: Efficient Interactions in Different Environments.,Hardegger LA, Kuhn B, Spinnler B, Anselm L, Ecabert R, Stihle M, Gsell B, Thoma R, Diez J, Benz J, Plancher JM, Hartmann G, Isshiki Y, Morikami K, Shimma N, Haap W, Banner DW, Diederich F ChemMedChem. 2011 Nov 4;6(11):2048-54. doi: 10.1002/cmdc.201100353. Epub, 2011 Sep 6. PMID:21898833[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|